If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
CKLF-like MARVEL transmembrane domain-containing 5 (CMTM5), previously termed chemokine-like factor superfamily 5 (i.e. CKLFSF5), designates any one of the six protein isoforms (termed CMTM5-v1 to CMTM5-v6) encoded by six different alternative splices of its gene, CMTM5; CMTM5-v1 is the most studied of these isoforms. The CMTM5 gene is located in band 11.2 on the long (i.e. "q") arm of chromosome 14. The CMTM5 isoforms are members of the CKLF-like MARVEL transmembrane domain-containing family (CMTM). This family consists of 9 proteins although most of them are known to have one or more isoforms. These proteins are: chemokine-like factor (i.e. CLF, the founding member of the family) and CEF-like marvel transmembrane domain-containing 1 through 8 (i.e. CMTM1 through CMTM8). All of these proteins as well as the genes responsible for their production (i.e. CKLF and CMTM1 to CMTM8, respectively) have similar structures but vary in their apparent physiological and pathological functions. Preliminary studies suggest that CMTM5-v1 (which cells commonly secrete to the extracellular spaces such as the blood) or an unspecified CMTM5 isoform has various functions including involvements in regulating the autoimmune system, the development of numerous types of cancers, and the cardiovascular system.
Ash is the solid remnants of fires. Specifically, ash refers to all non-aqueous, non-gaseous residues that remain after something burns. In analytical chemistry, to analyse the mineral and metal content of chemical samples, ash is the non-gaseous, non-liquid residue after complete combustion. Ashes as the end product of incomplete combustion are mostly mineral, but usually still contain an amount of combustible organic or other oxidizable residues. The best-known type of ash is wood ash, as a product of wood combustion in campfires, fireplaces, etc. The darker the wood ashes, the higher the content of remaining charcoal from incomplete combustion. The ashes are of different types. Some ashes contain natural compounds that make soil fertile. Others have chemical compounds that can be toxic but may break down in soil from chemical changes and microorganism activity. Like soap, ash is also a disinfecting agent (alkaline). The World Health Organization recommends ash or sand as alternative for handwashing when soap is not available. Before industrialization, ash soaked in water was the primary means of obtaining potash.
The NAD⁺-II riboswitch (also called the pnuC RNA motif) is a riboswitch found in bacteria that regulates gene expression in response to levels of nicotinamide adenine dinucleotide (NAD⁺) and related metabolites, particularly nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). A shorter variant, the mini-NAD⁺-II riboswitch, was described in 2025 and is more phylogenetically widespread than the original class. NAD⁺ is a ubiquitous enzyme cofactor that functions as a carrier of hydride ions in metabolic oxidation-reduction reactions. It also serves as a source of activated adenosine monophosphate (AMP) for adenylation reactions and as a precursor of ADP-ribose. Because of NAD⁺'s essential role in cellular metabolism, bacteria must carefully regulate genes involved in both the de novo biosynthesis and salvage (recycling) of NAD⁺ and its many derivatives. Two classes of NAD riboswitches have been identified: NAD-I and NAD⁺-II.
Blood compatibility testing is routinely performed before a blood transfusion. The full compatibility testing process involves ABO and RhD (Rh factor) typing; screening for antibodies against other blood group systems; and crossmatching, which involves testing the recipient's blood plasma against the donor's red blood cells as a final check for incompatibility. If an unexpected blood group antibody is detected, further testing is warranted to identify the antibody and ensure that the donor blood is negative for the relevant antigen. Serologic crossmatching may be omitted if the recipient's antibody screen is negative, there is no history of clinically significant antibodies, and their ABO/Rh type has been confirmed against historical records or against a second blood sample; and in emergencies, blood may be transfused before any compatibility testing results are available. Blood compatibility testing is often performed on pregnant women and on the cord blood from newborn babies, because incompatibility puts the baby at risk for developing hemolytic disease of the newborn. It is also used before hematopoietic stem cell transplantation, because blood group incompatibility can be responsible for some cases of acute graft-versus-host disease.
Sources: en.wikipedia.org
33. Eksp Klin Farmakol. 2006 Nov-Dec;69(6):13-6. [Comparative study of the effects of melatonin and epitalon on the protracted memory under the shuttle labyrinth test conditions in rats in the course of aging]. [Article in Russian] Vinogradova IA. The influence of the chronic administration of melatonin (epiphyseal hormone) and epitalon (a synthetic tetrapeptide increasing melatonin production) on the learning process and the protracted memory has been studied in LIO rats in the course of aging for 2 years under standard illumination regime (12L :12D). The daily administration of melatonin (Sigma, USA) with drinking water (in 10 mg/liter dose at night) in rats beginning with the age of 4 months did not influence the learning processes in young and adult animals but it was found to contribute to optimization of the brain cognitive function in rats in the course of aging, by improving the protracted memory process. Epitalon administered in a daily dose of 0.1 microg per animal beginning with the age of 4 months showed mnemotropic properties (decreasing the extent of memory disorders) in old rats under conditions of the shuttle labyrinth test.
8 October – Tánaiste Micheál Martin said that the Department of Foreign Affairs had been in touch with the family of Kim Damti (22), an Irish-Israeli woman who was unaccounted for following the previous day's series of attacks launched by Hamas on Israel. On 11 October, Damti was confirmed dead. 10 October – Minister for Finance Michael McGrath and Minister for Public Expenditure, National Development Plan Delivery and Reform Paschal Donohoe announced Budget 2024, with three electricity credits for all households, a €12 increase to core social welfare payments and half-price travel for those aged under 25. 23 October – Yousef Palani was sentenced to two life sentences plus 20 years for the murder of two men and the stabbing of a third in Sligo, all of who he had sought out on a pretence of dating. 25 October – The Health Products Regulatory Authority (HPRA) said it had seized 254 units of falsified Semaglutide, a drug used for type 2 diabetes and as an unofficial aide to weight loss, during 2023. 27 October – Latest figures showed that homelessness in Ireland hit new records: 8,923 adults and 3,904 children accessed emergency accommodation in September 2023, bringing the total to 12,827 people.
AS9100 Revision A (2001), Model for Quality Assurance in Design, Development, Production, Installation and Servicing During the rewrite of ISO 9001 for the 2000 release, the AS group worked closely with the ISO organization. As the year 2000 revision of ISO 9001 incorporated major organizational and philosophical changes, AS9000 underwent a rewrite as well. It was released as AS9100 to the international aerospace industry at the same time as the new version of ISO 9001. AS9100A was actually two standards referenced in one publication: Section 1 defines an updated QMS model aligned with the updated ISO 9001:2000 publication while Section 2 defines a legacy model aligned with ISO 9001:1994. Organizations that in the year 2001 were operating a QMS based on ISO 9001:1994 were permitted to conform to Section 2 with the expectation that they would then transition their QMS to Section 1.
Sources: pubmed.ncbi.nlm.nih.gov
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.